An Integrated Approach to Protein Discovery and Detection From Complex Biofluids

Area of Science:

• Oncology
• Biochemistry
• Biotechnology

Background:

• Ovarian cancer is a leading cause of cancer-related deaths in women.
• Early detection significantly improves survival rates but is challenging due to a lack of sensitive and specific screening methods.
• High-grade serous ovarian cancer, the most fatal form, often originates in the fallopian tubes, making vaginal sampling a proximal source for tumor detection.

Purpose of the Study:

• To develop a noninvasive screening method for early ovarian cancer detection.
• To identify reliable biomarkers in vaginal samples for early diagnosis.
• To overcome the limitations of current screening techniques in sensitivity and specificity.

Main Methods:

• Development of an untargeted mass spectrometry microprotein profiling method.
• Identification and validation of cystatin A as a potential biomarker in an animal model.
• Utilized a label-free microtoroid resonator to detect cystatin A at picomolar concentrations.
• Translated the workflow to patient-derived clinical samples.

Main Results:

• Cystatin A was identified as a potential biomarker for ovarian cancer.
• The method demonstrated the ability to detect cystatin A at 100 pM concentrations.
• The workflow was successfully translated to clinical samples, showing potential for early-stage detection.

Conclusions:

• Vaginal sampling combined with mass spectrometry offers a promising noninvasive approach for early ovarian cancer detection.
• Cystatin A is a potential biomarker for early-stage high-grade serous ovarian cancer.
• The developed method has the potential to improve early diagnosis and patient survival rates.